Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
|Articles|January 7, 2021
Mini-Quiz: Neurotransmitters
Author(s)Gerard Sanacora, MD, PhD
What is the most abundant and ubiquitous neurotransmitter in the mammalian central nervous system?
Advertisement
What is the most abundant and ubiquitous neurotransmitter in the mammalian central nervous system?
A. Acetylcholine
B. Dopamine
C. Glutamate
D. Serotonin
E. Norepinephrine
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Phase 2 MOONLIGHT-1 shows JNJ-5120/PIPE-307 misses day‑5 MADRS improvement in MDD, yet remains well tolerated as J&J reviews next steps.
Experts dissect 10 common antidepressant myths, separating evidence from fear on efficacy, addiction, suicide risk, withdrawal, and safe tapering.
Health Canada has authorized a 200-participant phase 2 trial testing a single psilocybin dose for major depressive disorder, with dosing set to begin in 2027.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
4
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
5